Literature DB >> 11725009

Oncogenes, Protein Tyrosine Kinases, and Signal Transduction.

D. Liu1, L.-H. Wang.   

Abstract

Many oncogenes encode protein tyrosine kinases (PTKs). Oncogenic mutations of these genes invariably result in constitutive activation of these PTKs. Autophosphorylation of the PTKs and tyrosine phosphorylation of their cellular substrates are essential events for transmission of the mitogenic signal into cells. The recent discovery of the characteristic amino acid sequences, of the src homology domains 2 and 3 (SH2 and SH3), and extensive studies on proteins containing the SH2 and SH3 domains have revealed that protein tyrosine-phosphorylation of PTKs provides phosphotyrosine sites for SH2 binding and allows extracellular signals to be relayed into the nucleus through a chain of protein-protein interactions mediated by the SH2 and SH3 domains. Studies on oncogenes, PTKs and SH2/SH3-containing proteins have made a tremendous contribution to our understanding of the mechanisms for the control of cell growth, oncogenesis, and signal transduction. This review is intended to provide an outline of the most recent progress in the study of signal transduction by PTKs. Copyright 1994 S. Karger AG, Basel

Entities:  

Year:  1994        PMID: 11725009     DOI: 10.1007/bf02257980

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  4 in total

1.  Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ros: biological function and substrate interaction.

Authors:  C S Zong; L H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

2.  Use of double-stranded RNA-mediated interference to determine the substrates of protein tyrosine kinases and phosphatases.

Authors:  Marco Muda; Carolyn A Worby; Nancy Simonson-Leff; James C Clemens; Jack E Dixon
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

3.  Journal of hematology & oncology: a journal open to all.

Authors:  Delong Liu
Journal:  J Hematol Oncol       Date:  2008-05-28       Impact factor: 17.388

Review 4.  Novel agents for advanced pancreatic cancer.

Authors:  Akintunde Akinleye; Chaitanya Iragavarapu; Muhammad Furqan; Shundong Cang; Delong Liu
Journal:  Oncotarget       Date:  2015-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.